OIPE TO				GA	U/65/ }
RADEMARK	sign (+) inside this box		U.S. Patent and Tradem	PTO/s red for use through 10/31/2002. OM ark Office: U.S. DEPARTMENT OR on unless it displays a valid OMB co	BOSSI 6034 COMMERCE VF
	<u></u>		Application Number	09/327,761	NOV 14 2000
TRANSMITTAL FORM (to be used for all correspondence after initial filing)			Filing Date	June 7, 1999	
			First Named Inventor	Donald W. Peters	CH CENTER 18 10/2900 en
			Group Art Unit	1651	
			Examiner Name	Jean C. Witz	
Total Number of Pages in This Submission 4			Attomey Docket Number	99,501	<u> </u>
ENCLOSURES (check all that apply)					
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53		Assignment Papers (for an Application) Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter X Other Enclosure(s) (please identify below): Election/Restriction (4 pages); return receipt post card.	
	SIGNATI	URE OF APPL	ICANT, ATTORNEY, OR	AGENT	
Firm or Individual name	Jarry W. McKenzie Peg No · 28 239				
Signature Larry w mich					
Date 11-3-00					
		CERTIFIC	ATE OF MAILING		
I hereby certify that this cor mail in an envelope addres	respondence is being sed to: Commissione	deposited with the for Patents, Wa	the United States Postal Servishington, DC 20231 on this contractions	ice with sufficient postage as findate:	st class
Typed or printed name Larry W. McKenzie Reg. No.: 28,239					
Signature Larun w hacher Date 11-3-(17)					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Re: Patent Application

RECEIVED

NOV 1 4 2000

TECH CENTER 1600/2900

Group Art Unit: 1651

Election/Restriction

Docket No.: 99,501

Examiner: Jean C. Witz

TED STATES PATENT AND TRADEMARK OFFICE

Applicants:

1

2

7

8

Donald W. Petersen

Warren O. Haggard Donald A. Randolph

Cary P. Hagan

Assignee: Wright Medical Technology, Inc.

Application No.: 09/327,761

Filed: June 7, 1999

For: Bone Graft Substitute Composition

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

ELECTION / RESTRICTION

In response to the Office communication mailed October 4, 2000, please cancel claims 1, 5-7 and 9-11, and please amend claims 2, 8 and 12 as follows:

Claim 2 (amended). A bone graft substitute composition comprising:

(a) calcium sulfate;

(b) a mixing solution selected from the group consisting of sterile water, inorganic salts, and cationic surface active agants including sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, ammonium sulfate, ammonium acetate, and sodium acetate;

(c) a plasticizing substance selected from the group consisting of cellulose

- derivatives including sodium carboxymethylcellulose, methycellulose, hydroxypropyl
- methylcellulose, ethylcellulose, hydroxethylcellulose and cellulose acetate butyrate, and 9
- higher molecular weight alcohols including glycerol and vinyl alcohols; and [The bone 10
- graft substitute composition of claim 1 in which is included] 11
- 12 (d) demineralized bone matrix.

1 Claim 8 (amended). A bone graft substitute composition comprising: RECEIVEL 2 (a) calcium sulfate; (b) a mixing solution selected from the group consisting of sterile water, inorganic 3 salts, and cationic surface active agents including sodium chloride, phosphate buffered 4 5 saline, potassium chloride, sodium sulfate, ammonium sulfate, ammonium acetate, and 6 sodium acetate; (c) a plasticizing substance selected from the group consisting of cellulose derivatives including sodium carboxymethylcellulose, methycellulose, hydroxypropyl methylcellulose, ethylcellulose, hydroxethylcellulose and cellulose acetate butyrate, and higher molecular weight alcohols including glycerol and vinyl alcohols; and [The bone 11 graft substitute composition of claim 1 in which is included] (d) a bioactive agent selected from the group consisting of demineralized bone 12 matrix, growth factors, hyaluronic acid, bone morphogenic proteins, bone autograft, 13 therapeutic agents, analgesics, and bone marrow, bone allograft, and parenchymal and 14 15 mesenchymal cells. Claim 12 (amended). A bone graft substitute composition comprising: 1 (a) approximately 80-120 parts medical grade calcium sulfate hemihydrate by weight: (b) approximately 21-250 parts sterile water by weight; and (c) approximately 1-40 parts sodium carboxymethylcellulose by weight; and [The bone graft substitute of claim 11 in which is included] (d) approximately 10-100 parts demineralled bone matrix by weight.

j